Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Shareholder Meeting (November 2022)
22 slides from Island Pharmaceuticals's shareholder meeting presentation, Nov 17, 2022
Slide 1: Solving Urgent Viral Disease Threats
For personal use only SOLVING URGENT VIRAL DISEASE THREATS (ASX: ILA) 2022 Annual General Meeting CEO’s presentation November 2022 ISLAND PHARMACEUTICALS LIMITED 1 Investor AGM Presentation PRESENTATION – October 2022 – NOVEMBER 2021
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited views on its future performance or condition. Actual results could differ No representation, warranty or assurance (express or implied) is given For personal use only (ABN 641 183 842) (Company or Island Pharmaceuticals
Slide 3: Mid clinical-stage drug repurposing company for antivirals
For personal use only Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases ISLAND PHARMACEUTICALS LIMITED 3 Investor AGM Presentation PRESENTATION – October 2022 – NOVEMBER 2021
Slide 4: Island at a Glance
ISLAND AT A GLANCE For personal use only Advancing lead drug Dengue infects +390 million year Major market potential ISLA-101 toward Phase 2 No current pharmaceutical treatment In mosquito-borne “PEACH” clinical trial for the for the disease. Limited access to only diseases, exacerbated by preventio
Slide 5: The Challenge
For personal use only THE CHALLENGE ISLAND PHARMACEUTICALS LIMITED 5 Investor AGM Presentation PRESENTATION – October 2022 – NOVEMBER 2021
Slide 6: Dengue fever is the most rapidly spreading mosquito-borne virus infection
For personal use only “DENGUE FEVER IS THE MOST RAPIDLY SPREADING MOSQUITO-BORNE VIRUS INFECTION IN THE WORLD.” World Health Organisation, 13 October 2022 ISLAND PHARMACEUTICALS LIMITED 6 Investor AGM Presentation PRESENTATION – October 2022 – NOVEMBER 2021
Slide 7: Mosquito Borne Viruses: Global Challenges
MOSQUITO BORNE VIRUSES: GLOBAL CHALLENGES For personal use only Nov 23, 2021 Dec 1, 2021 The researchers found 2.4 times the rate of arbovirosis as originally reported, including coinfections, suggesting underestimation of the incidence of the three viruses. However, future research is needed to pro
Slide 8: Why Dengue as a First Target for ISLA-101?
WHY DENGUE AS A FIRST TARGET FOR ISLA-101? SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE For personal use only Significant unmet need (3.9 billion people at risk) Increasing spread to US, EU and Australia ISLA-101 has both therapeutic and prophylactic potential Strong animal and human
Slide 9: Dengue Is a Widespread Issue
DENGUE IS A WIDESPREAD ISSUE For personal use only Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands. ISLAND PHARMACEUTICALS LIMITED https://www.healthmap.org/dengue/en/ visited November 1, 2022 9 Investor AGM Presentatio
Slide 10: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE For personal use only Prediction based on projections of future temperatures, rainfall, and mosquito populations (NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford.) ISLAND PHARMACEUTICALS LIMITED https://earthobserv
Slide 11: Limited Available Solutions
LIMITED AVAILABLE SOLUTIONS HIGHLY PREVALENT DISEASES WITH UNMET MEDICAL NEED For personal use only Deformities in babies from mothers with Zika Dengue Zika Yellow Japanese West Nile fever Virus fever Encephalitis Viral diseases are a Worldwide 390 Up to n/a 130,000 70,000 leading cause of prevalenc
Slide 12: ISLA-101
For personal use only ISLA-101 ISLAND PHARMACEUTICALS LIMITED 12 Investor AGM Presentation PRESENTATION – October 2022 – NOVEMBER 2021
Slide 13: ISLA-101 Repurposed Drug
ISLA-101 REPURPOSED DRUG DRAMATICALLY REDUCES DEVELOPMENT TIME, RISK AND COST For personal use only ISLA-101, originally Demonstrated Strong regulatory Speed to market Capitalising on a cancer drug as safe in humans history and & early revenue millions spent acceptance potential Originally identifie
Slide 14: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES (A SUBGROUP OF ARBOVIRUSES) IN MULTIPLE MODELS OF INFECTION For personal use only • In in-vitro models using fresh human cells, Dengue 1-4 ISLA-101 has demonstrated broad anti-viral activity • In animal models, ISLA-101 is pr
Slide 15: Pathway / Timing to Clinical Trials
PATHWAY / TIMING TO CLINICAL TRIALS MULTIPLE WORKSTREAMS WILL TAKE US TO FDA REVIEW OF OUR IND For personal use only 1. Manufacturing complete, awaiting 30 day stability. 2. Finalization of CMC section of IND IND Mandatory Island trial submitted 30-day commences!* 3. Completion of Protocol review pe
Slide 16: Manufacturing Progress
MANUFACTURING PROGRESS For personal use only Manufactured Packaged bottles capsules being awaiting stability processed results ISLAND PHARMACEUTICALS LIMITED 16 Investor AGM Presentation PRESENTATION – October 2022 – NOVEMBER 2021
Slide 17: Phase II Dengue (PEACH) Trial Study in Detail
PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL “PEACH" STUDY- A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE MODEL For personal use only Administer ISLA-101 daily Phase II trial protocol Up to 4 cohorts/4 arms Incl
Slide 18: The Commercial Opportunity
For personal use only THE COMMERCIAL OPPORTUNITY ISLAND PHARMACEUTICALS LIMITED 18 Investor AGM Presentation PRESENTATION – October 2022 – NOVEMBER 2021
Slide 19: Commercial Opportunity
COMMERCIAL OPPORTUNITY For personal use only Prophylactic for National Government Priority Review travelers Military outbreaks Stockpiles Voucher Tropical area travellers opportunity: Military opportunity: Endemic area opportunity: • Comparable to malaria market – • Isla is partnering with army (CRA
Slide 20: Timeline Now Falling Into Place
TIMELINE NOW FALLING INTO PLACE For personal use only H1 FY 2022 H2 FY 2022 H1 FY 2023 H2 FY 2023 (July-Dec 2021) (Jan-June 2022) (July-Dec 2022) (Jan-June 2023) New drug product Clinical material • Open IND Sign SUNY CTA manufacturer manufactured • Screening, Announce Principal secured Inve
Slide 21: Board, Management & Scientific Board
BOARD, MANAGEMENT & SCIENTIFIC BOARD For personal use only BOARD & MANAGEMENT TEAM Dr. Paul MacLeman Dr. David Foster Dr. Anna Lavelle Mr. Al Hansen Dr. David Brookes Executive Chair CEO & Executive Director Non-Executive Director Non-Executive Director Non-Executive Director SCIENTIFIC ADVISORY BOA
Slide 22: David Foster, CEO contact details
For personal use only David Foster Chief Executive Officer & Executive Director dfoster@islandpharmaceuticals.com Authorized for release by Paul MacLeman, Executive Chairman Island Pharmaceuticals www.islandpharmaceuticals.com Limited Registered office: Suite 201, ISLAND PHARMACEUTICALS 697 Burke Rd
Island Pharmaceuticals — Shareholder Meeting (November 2022) on 6ix